Cart
sales@molnova.com
Pinoresinol diglucoside
CAS No. 63902-38-5
Pinoresinol diglucoside ( —— )
Catalog No. M18941 CAS No. 63902-38-5
Pinoresinol diglucoside is a putative α-glucosidase inhibiting compound. 2. Pinoresinol diglucoside is a important antihypertensive compound.
Purity : 96%
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 41 | In Stock |
|
| 10MG | 73 | In Stock |
|
| 50MG | 263 | In Stock |
|
| 100MG | 478 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePinoresinol diglucoside
-
NoteResearch use only, not for human use.
-
Brief DescriptionPinoresinol diglucoside is a putative α-glucosidase inhibiting compound. 2. Pinoresinol diglucoside is a important antihypertensive compound.
-
DescriptionPinoresinol diglucoside is a putative α-glucosidase inhibiting compound. Pinoresinol diglucoside is a important antihypertensive compound.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
Recptorα-glucosidase
-
Research AreaOthers-Field
-
Indication——
Chemical Information
-
CAS Number63902-38-5
-
Formula Weight682.67
-
Molecular FormulaC32H42O16
-
Purity96%
-
Solubility——
-
SMILESCOC1=C(C=CC(=C1)C2C3COC(C3CO2)C4=CC(=C(C=C4)OC5C(C(C(C(O5)CO)O)O)O)OC)OC6C(C(C(C(O6)CO)O)O)O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PLP 139-151
PLP (139-151) is amino acid residue residue 139 to 151 of myelin proteolipid protein (PLP). This peptide is used to induce relapsing-remitting (RR)-EAE model.
-
Ganoderic acid GS-2
Ganoderic acid GS-2 can inhibit the activity of human immunodeficiency virus -1 protease.
-
BMS986260
BMS-986260 is a selective, and orally bioavailable TGFβR1 inhibitor(IC50 = 1.6 nM). BMS-986260?demonstrated functional activity in multiple TGFβ-dependent cellular assays, excellent kinome selectivity, favorable pharmacokinetic properties, and curative in vivo efficacy in combination with anti-PD-1 antibody in murine colorectal cancer (CRC) models.?
